Rachel L Randell, Stephen J Balevic, Rachel G Greenberg, Michael Cohen-Wolkowiez, Elizabeth J Thompson, Saranya Venkatachalam, Michael J Smith, Catherine Bendel, Joseph M Bliss, Hala Chaaban, Rakesh Chhabra, Christiane E L Dammann, L Corbin Downey, Chi Hornik, Naveed Hussain, Matthew M Laughon, Adrian Lavery, Fernando Moya, Matthew Saxonhouse, Gregory M Sokol, Andrea Trembath, Joern-Hendrik Weitkamp, Christoph P Hornik
Pharmacokinetic models rarely undergo external validation in vulnerable populations such as critically ill infants, thereby limiting the accuracy, efficacy, and safety of model-informed dosing in real-world settings. Here, we describe an opportunistic approach using dried blood spots (DBS) to evaluate a population pharmacokinetic model of metronidazole in critically ill preterm infants of gestational age (GA) ≤31 weeks from the Metronidazole Pharmacokinetics in Premature Infants (PTN_METRO, NCT01222585) study...
March 13, 2024: Antimicrobial Agents and Chemotherapy